Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
Carneiro Neto, Jose Abraão; Santos, Silvane Braga; Orge, Gloria Orge; Tanajura, Davi; Passos, Lucia; Oliveira, Cassius José; Andrade, Rosana; Melo, Cláudio Galeno de; Barroso Jr, Ubirajara; Carvalho, Edgar M.
Braz. j. infect. dis
; 22(2): 79-84, Mar.-Apr. 2018. tab, graf
Artigo
Inglês
| LILACS | ID: biblio-951636
ABSTRACT
Aim:
To evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on quality of life (QoL).Methods:
Case series with 10 patients with overactive bladder refractory to conservative treatment with anticholinergic or physical therapy. They received 200Ui of onabotulinumtoxin type A intravesically and were evaluated by overactive bladder symptoms score (OABSS) and King's Health Questionnaire.Results:
The mean (SD) of the age was 52 + 14.5 years and 60% were female. All of them had confirmed detrusor overactivity on urodynamic study. Seven patients had HAM/TSP. The median and range of the OABSS was 13 (12-15) before therapy and decreased to 1.0 (0-12) on day 30 and to 03 (0-14) on day 90 (p < 0.0001). There was a significant improvement in 8 of the 9 domains of the King's Health Questionnaire after the intervention. Hematuria, urinary retention and urinary infection were the complications observed in 3 out of 10 patients. The mean time to request retreatment was 465 days.Conclusion:
Onabotulinum toxin type A intravesically reduced the OABSS with last long effect and improved the quality of life of HTLV-1 infected patients with severe overactive bladder.
Biblioteca responsável:
BR1.1
Texto completo
Documentos relacionados
